Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal. The big Swiss pharma will pay $750 million cash up front and $ ...

Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

Roche entered into a worldwide partnership with Sarepta Therapeutics in 2019 to commercialise the gene therapy outside of the US. Subjects in the trial received one dose of Elevidys or a placebo ...

As part of a collaboration agreement signed in 2019, Sarepta is working with Roche (RHHBY) to transform the future for the Duchenne community, enabling those living with the disease to maintain ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Roche Holding AG (RHHVF – Research Report). Sarepta ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

Ex-US, Elevidys will be marketed and sold by Roche Holding AG (OTCQX:RHHBY), the Swiss Pharma giant, who paid Sarepta ~$1.15bn upfront, plus an additional $1.7bn of milestones related to ...

Sarepta recorded around $37.4 million as collaboration and other revenues associated with commercial Elevidys supply to Roche. This metric also included $9.5 million received as royalty revenues ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

No new safety signals were observed. As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is responsible for regulatory approval and ...

Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained ...